UBS has recently announced its continued investment in Novartis AG, a well-known global pharmaceutical company that specializes in the development, manufacturing, and marketing of a wide range of pharmaceutical products.

Novartis AG's sales are primarily driven by various therapeutic areas. Oncology accounts for 29.9% of sales, immunology at 17.2%, and cardiovascular, renal, and metabolic diseases contribute 14.1%. Additionally, neuroscience represents 8.9% of sales, while contract manufacturing of pharmaceutical products makes up the remaining 29.9%.

As of the end of 2023, Novartis AG operates 33 production sites worldwide, showcasing its extensive manufacturing capabilities. Geographically, the company's sales distribution is notable. Europe contributes 33% of sales, the USA at 39.5%, Asia-Africa-Australasia at 20.5%, and Canada and Latin America account for 7%. Novartis AG's diverse portfolio and global reach establish it as a significant player in the pharmaceutical industry.